Asthma,Chronic Obstructive Pulmonary Disease Asthma,Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Vibrating mesh nebulizer group: Starting 10 minutes after initiation of HFNC, a mixture of 2.5 mg salbutamol and 5 mL of 0.9% normal saline will be administered via inhalation over a period of 20 minu
Sponsors
Okuda Miyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients clinically diagnosed with asthma or COPD by the principal investigator or sub-investigator. (2)Patients whose medication for asthma or COPD has not changed for one month prior to obtaining consent, whose condition is stable, and who can discontinue bronchodilators or inhaled corticosteroids. (3)Patients capable of undergoing a bronchodilator reversibility test. (4)Patients with an ECOG performance status of 0 to 2 . (5)Patients who have received sufficient explanation about participation in this study,fully understand it, and have provided written consent of their own free will. (6)Patients aged 18 or older at the time of consent
Exclusion criteria
Exclusion criteria: (1) Patients aged 90 years or older. (2) Pregnant patients or patients who may be pregnant. (3) Patients who are breastfeeding or may breastfeed. (4) Patients with a history of exacerbation of pulmonary disease requiring hospitalization within three months prior to obtaining consent. (5) Patients who have developed pneumothorax within three months prior to obtaining consent. (6) Patients who have developed acute coronary syndrome within three months prior to obtaining consent. (7) Patients with a thoracoabdominal aortic aneurysm. (8) Patients with active hemoptysis. (9) Patients with a salbutamol allergy. (10) Patients undergoing oxygen therapy. (11) Patients currently receiving biological agents or those who have received them within the past six months. (12) Patients deemed unsuitable for participation in this study by the principal investigator or sub-investigator . (13) Patients with asthma-COPD overlap. (14) Patients who have received oral or intravenous steroids within one month prior to obtaining consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in dose per second after SABA inhalation | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events during SABA inhalation Change from baseline in lung function after SABA inhalation | — |
Contacts
Public ContactMiyuki Okuda
NHO Osaka Minami Medical Center
Outcome results
None listed